Reported Standalone quarterly numbers for Alembic Pharmaceuticals are:Net Sales at Rs 1,475.56 crore in June 2024 up 10.75% from Rs. 1,332.27 crore in June 2023.
Quarterly Net Profit at Rs. 176.19 crore in June 2024 up 80.66% from Rs. 97.53 crore in June 2023.
EBITDA stands at Rs. 294.57 crore in June 2024 up 65.89% from Rs. 177.57 crore in June 2023.
Alembic Pharma EPS has increased to Rs. 8.96 in June 2024 from Rs. 4.96 in June 2023.
| Alembic Pharma shares closed at 1,110.80 on August 12, 2024 (NSE) and has given 14.36% returns over the last 6 months and 40.50% over the last 12 months. |
| Alembic Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'24 | Mar'24 | Jun'23 | | Net Sales/Income from operations | 1,475.56 | 1,474.55 | 1,332.27 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 1,475.56 | 1,474.55 | 1,332.27 | | EXPENDITURE | | Consumption of Raw Materials | 405.93 | 337.38 | 334.19 | | Purchase of Traded Goods | 94.36 | 109.20 | 89.95 | | Increase/Decrease in Stocks | -111.68 | -25.25 | -7.20 | | Power & Fuel | -- | -- | -- | | Employees Cost | 356.51 | 354.92 | 327.47 | | Depreciation | 68.68 | 69.12 | 65.75 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 439.01 | 410.11 | 422.13 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 222.75 | 219.07 | 99.98 | | Other Income | 3.15 | 7.22 | 11.84 | | P/L Before Int., Excpt. Items & Tax | 225.89 | 226.29 | 111.82 | | Interest | 12.69 | 10.13 | 14.29 | | P/L Before Exceptional Items & Tax | 213.20 | 216.16 | 97.53 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 213.20 | 216.16 | 97.53 | | Tax | 37.01 | 14.29 | -- | | P/L After Tax from Ordinary Activities | 176.19 | 201.87 | 97.53 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 176.19 | 201.87 | 97.53 | | Equity Share Capital | 39.31 | 39.31 | 39.31 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 8.96 | 10.27 | 4.96 | | Diluted EPS | 8.96 | 10.27 | 4.96 | | EPS After Extra Ordinary | | Basic EPS | 8.96 | 10.27 | 4.96 | | Diluted EPS | 8.96 | 10.27 | 4.96 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
